Zealand Pharma shares plummeted 26% on June 8, 2026, after safety data showed 19% of patients in its survodutide obesity drug study dropped out due to gastrointestinal events versus 2.9% on placebo, with over 40% reporting vomiting. The company has licensed survodutide to Boehringer Ingelheim. Zealand Pharma stock is down nearly 50% year-to-date following earlier disappointment with its petrelintide trial.
Survodutide safety concerns
- ▪Zealand Pharma has licensed survodutide to privately-held Boehringer Ingelheim
- ▪More than 40% of patients in the survodutide study reported vomiting
- ▪Survodutide topline data announced in April 2026 showed average weight loss of up to 16.6% versus 3.2% with placebo
- ▪Zealand Pharma CEO Adam Steensberg told CNBC in March 2026 that Zealand Pharma was extremely certain there would be a shift in the industry towards tolerability
- ▪Survodutide was tested in adults living with obesity or overweight adults without type 2 diabetes over 76 weeks
- ▪19% of patients in the survodutide late-stage study dropped out due to gastrointestinal events, compared to 2.9% on placebo
Zealand Pharma stock decline
- ▪Zealand Pharma shares plummeted as much as 26% on June 8, 2026
- ▪Zealand Pharma stock has dropped nearly 50% year-to-date as of June 8, 2026
- ▪Zealand Pharma stock suffered its worst day on record approximately three months before June 8, 2026, when a trial of petrelintide disappointed investors with lower-than-expected weight loss statistics
- ▪Zealand Pharma shares were down 25% on June 8, 2026, at the bottom of the pan-European Stoxx 600 index
Petrelintide trial results
- ▪Zealand Pharma is developing petrelintide together with Roche
- ▪Further data on petrelintide was disclosed on June 5, 2026
Weight loss drug market competition
- ▪Amgen and AstraZeneca are testing their own anti-obesity drugs
- ▪Zealand Pharma is partnering with Roche and Boehringer Ingelheim on anti-obesity drugs
- ▪Eli Lilly sells tirzepatide as Zepbound and Mounjaro
- ▪Novo Nordisk sells semaglutide under the brand names Wegovy and Ozempic
Story comments
Loading comments…